Connect Biopharma (NASDAQ:CNTB - Get Free Report) was upgraded by Wall Street Zen to a "hold" rating in a report released on Friday.
Other equities research analysts also recently issued research reports about the stock. Northland Capmk upgraded shares of Connect Biopharma to a "strong-buy" rating in a research report on Tuesday, July 22nd. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Connect Biopharma in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Strong Buy" and a consensus target price of $7.00.
View Our Latest Report on CNTB
Connect Biopharma Stock Performance
Shares of NASDAQ:CNTB opened at $1.83 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.24 and a current ratio of 7.24. Connect Biopharma has a 52 week low of $0.51 and a 52 week high of $2.86. The firm has a 50 day simple moving average of $1.62 and a 200 day simple moving average of $1.08.
Institutional Investors Weigh In On Connect Biopharma
Several institutional investors and hedge funds have recently modified their holdings of the business. AlphaCore Capital LLC acquired a new stake in shares of Connect Biopharma in the 2nd quarter valued at $78,000. Koa Wealth Management LLC bought a new position in Connect Biopharma in the 2nd quarter worth $49,000. Finally, XTX Topco Ltd bought a new position in Connect Biopharma in the 2nd quarter worth $29,000. Institutional investors and hedge funds own 58.72% of the company's stock.
Connect Biopharma Company Profile
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access